检验医学 ›› 2020, Vol. 35 ›› Issue (7): 710-715.DOI: 10.3969/j.issn.1673-8640.2020.07.019

• 技术研究与评价·论著 • 上一篇    下一篇

基于高通量靶向测序的常见实体肿瘤基因突变图谱研究

陈慧娟1, 王景2, 王爱琴2   

  1. 1.北京工业大学生命科学与生物工程学院,北京 100124
    2.北京博奥医学检验所有限公司,北京 101111
  • 收稿日期:2019-03-25 出版日期:2020-07-30 发布日期:2020-08-04
  • 作者简介:null

    作者简介:陈慧娟,女,1983年生,博士,主要从事肿瘤相关的分子诊断研究。

Genetic mutation profiling of solid tumors based on targeted-based next generation sequencing

CHEN Huijuan1, WANG Jing2, WANG Aiqin2   

  1. 1. College of Life Sciences and Bio-Engineering,Beijing University of Technology,Beijing 100124,China
    2. Beijing Capitalbio Medlab Co.,Beijing 101111,China
  • Received:2019-03-25 Online:2020-07-30 Published:2020-08-04

摘要:

目的 采用含有50个基因组合的高通量靶向测序技术检测多种实体肿瘤的基因突变情况,分析实体肿瘤的基因突变情况,了解实体肿瘤的基因突变图谱,为临床诊疗提供理论依据。方法 收集367例多种类型实体肿瘤样本,采用BES 4000平台检测50个基因状态,分析各种肿瘤中的基因突变情况。结果 367例样本中,64.03%的样本至少存在1种基因的突变;共检测到28种基因突变,突变率从高到低的前9个基因分别为EGFR(32.15%)、TP53(15.53%)、K-ras(8.17%)、c-kit(5.72%)、APC(3.00%)、PTEN(3.00%)、B-raf(2.72%)、ERBB2(2.72%)和PIKC3CA(2.72%)。在非小细胞肺癌中突变率最高的基因为EGFR(40.10%),该基因突变在本研究其他恶性实体肿瘤中未被发现。在非小细胞肺癌(NSCLC)、结直肠癌、胃癌和卵巢癌中均检测到TP53的突变,突变率分别为13.61%、34.38%、33.30%和50.00%。在结直肠癌中突变率最高的基因为K-ras(42.86%),胃肠间质瘤中突变率最高的基因为c-kit(53.13%)。在被检测到突变的样本中,28.97%(68/235)的样本存在基因的共突变,TP53的共突变率最高为16.60%(39/235)。统计学分析结果显示,是否发生基因突变与患者性别和年龄无关,但TP53基因突变在≥58岁患者明显高于<58岁患者(P<0.001)。在非小细胞肺癌中,女性(P<0.01)、肺腺癌(P<0.001)患者EGFR突变率较高;ERBB2在<58岁患者中突变率较高(P=0.001)。结论 不同肿瘤中存在不同基因突变图谱,TP53基因突变发生多种实体肿瘤中并且与年龄相关,高通量靶向测序技术可同时检测多种基因的突变情况,为临床治疗决策提供全面指导。

关键词: 高通量测序, 基因突变, 实体肿瘤

Abstract:

Objective To detect the genetic mutations of solid tumors with a 50-gene hotspot mutational panel,and to interrogate the genetic mutation profiling of solid tumors. Methods A total of 367 various types of solid tumor samples were collected,and the genetic mutation with a 50-gene hotspot mutational panel based on BES 4000 platform was determined. Results Among the 367 solid tumor samples,64.03% samples had at least one gene mutation. Different genetic mutations in 28 genes were determined,and the most frequency mutated genes were EGFR(32.15%),TP53(15.53%),K-ras(8.17%),c-kit(5.72%),APC(3.00%),PTEN(3.00%),B-raf(2.72%),ERBB2(2.72%) and PIK3CA(2.72%). In non-small cell lung cancer(NSCLC),the most frequency mutated gene was EGFR(40.10%),and EGFR mutation just harbored in NSCLC patients. TP53 mutation was found at NSCLC,colorectal cancer,gastric cancer and ovarian cancer patients,and the mutation frequencies were 13.61%,34.38%,33.30% and 50.00%,respectively. K-ras(42.86%) was the most frequency mutated gene in colorectal cancer patients,and that in gastrointestinal stromal tumor was c-kit(53.13%). Among 235 gene mutation samples,28.97%(68/235) had at least 2-gene comutation,and TP53 comutation rate was the highest as 16.60%(39/325). There was no correlation between whether harbored gene mutation and sex,age. The mutation rate of TP53 in ≥58-year-old patients was higher than that <58-year-old patients(P<0.001). In NSCLC,females(P<0.01) and patients with adenocarcinoma(P<0.001) were prone to carry EGFR mutation,and <58-year-old patients were prone to carry ERBB2 mutation. Conclusions Different genetic mutation profiling is determined in solid tumors,TP53 mutation is found in various types of solid tumors and is correlated with patients' age. Target-based next generation sequencing can identify the genetic mutation profiling in solid tumors and provide a reference for clinical treatment.

Key words: Next generation sequencing, Genetic mutation, Solid tumor

中图分类号: